Geovax announces gedeptin® presentation at the aacr-ahns head and neck cancer conference

Atlanta, ga, june 28, 2023 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that an abstract regarding geovax's gene therapy candidate, gedeptin®, has been selected for poster presentation at the american association for cancer research (aacr) and the american head and neck society (ahns) joint head and neck cancer conference, being held from july 7-8, 2023 at the palais des congrÈs de montrÉal in montrÉal, qc, canada.
GOVX Ratings Summary
GOVX Quant Ranking